{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:06:28Z","timestamp":1785240388869,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clml.2026.04.001","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T14:39:02Z","timestamp":1776177542000},"page":"e841-e852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Timing of Tyrosine Kinase Inhibitor Switching in Chronic Myeloid Leukemia: A Comparative Analysis of Early Versus Late Strategies"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7696-6800","authenticated-orcid":false,"given":"Chidiebube","family":"Ugwu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1438-2698","authenticated-orcid":false,"given":"Tarfa","family":"Verinumbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folajimi","family":"Atunde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9630-657X","authenticated-orcid":false,"given":"Ana","family":"Chachua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4229-0455","authenticated-orcid":false,"given":"Nneoma","family":"Ubah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muluken","family":"Megiso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angimar","family":"Uriepero-Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4522-4680","authenticated-orcid":false,"given":"Sam","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvis","family":"Obomanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colton","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor","family":"Varadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7231-2623","authenticated-orcid":false,"given":"Alankrita","family":"Taneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.clml.2026.04.001_bib0001","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2026.04.001_bib0002","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.clml.2026.04.001_bib0003","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2026.04.001_bib0004","doi-asserted-by":"crossref","first-page":"175","DOI":"10.4103\/0971-5916.164250","article-title":"Molecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase","volume":"142","author":"Malhotra","year":"2015","journal-title":"Indian J Med Res"},{"issue":"20","key":"10.1016\/j.clml.2026.04.001_bib0005","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2026.04.001_bib0006","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: eNESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2026.04.001_bib0007","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","article-title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final 5-year results from the BFORE trial","volume":"36","author":"Br\u00fcmmendorf","year":"2022","journal-title":"Leukemia"},{"issue":"5682","key":"10.1016\/j.clml.2026.04.001_bib0008","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.clml.2026.04.001_bib0009","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.clml.2026.04.001_bib0010","first-page":"2849","article-title":"Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotinib or imatinib: systematic review and meta-analysis","volume":"148","author":"Li","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.001_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1113462","article-title":"Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: characteristics, potential mechanisms, and clinical management strategies","volume":"13","author":"Cheng","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.04.001_bib0012","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyad225","article-title":"Association of Nilotinib with cardiovascular diseases in patients with chronic myelogenous leukemia: a national population-based cohort study","volume":"29","author":"Huang","year":"2024","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.clml.2026.04.001_bib0013","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2026.04.001_bib0014","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.clml.2026.04.001_bib0015","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","article-title":"Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib","volume":"123","author":"Hughes","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2026.04.001_bib0016","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1038\/s41375-020-0805-1","article-title":"Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CMLCP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study","volume":"34","author":"Cortes","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2026.04.001_bib0017","first-page":"1362","article-title":"Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to 3 months of imatinib therapy: final 5-year results from DASCERN","volume":"109","author":"Cortes","year":"2024","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.clml.2026.04.001_bib0018","first-page":"2421","article-title":"Evaluation of real-world versus clinical trial outcomes of tyrosine kinase inhibitor therapy for chronic myeloid leukemia","volume":"103","author":"Collins","year":"2024","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.clml.2026.04.001_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2024.12.015","article-title":"Real world evidence from 2 decades of first-line TKI therapy in chronic myeloid leukemia (CML): insights from ACHO\u2019s RENEHOC registry","volume":"25","author":"Abello Polo","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.clml.2026.04.001_bib0020","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"125","author":"Valent","year":"2015","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.clml.2026.04.001_bib0021","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.04.001_bib0022","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/ajh.25306","article-title":"Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY","volume":"94","author":"Hehlmann","year":"2019","journal-title":"Am J of Hematology"},{"issue":"1","key":"10.1016\/j.clml.2026.04.001_bib0023","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41408-025-01242-8","article-title":"Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study","volume":"15","author":"Busque","year":"2025","journal-title":"Blood Cancer J"},{"issue":"suppl_4","key":"10.1016\/j.clml.2026.04.001_bib0024","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.clml.2026.04.001_bib0025","first-page":"5096","article-title":"Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients","volume":"116","author":"Jabbour","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clml.2026.04.001_bib0026","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/hematology.2021000240","article-title":"Blast and accelerated phase chronic myeloid leukemia: room for improvement","volume":"2021","author":"How","year":"2021","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"4","key":"10.1016\/j.clml.2026.04.001_bib0027","first-page":"808","article-title":"Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era \u2013 analysis of the European LeukemiaNet Blast Phase Registry","volume":"38","author":"Nicolini","year":"2024","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2026.04.001_bib0028","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"issue":"5","key":"10.1016\/j.clml.2026.04.001_bib0029","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4082\/kjfm.2015.36.5.197","article-title":"An overview and update of chronic myeloid leukemia for primary care physicians","volume":"36","author":"Granatowicz","year":"2015","journal-title":"Korean J Fam Med"},{"issue":"23","key":"10.1016\/j.clml.2026.04.001_bib0030","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.clml.2026.04.001_bib0031","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2026.04.001_bib0032","first-page":"123","article-title":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Hochhaus","year":"2025","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2026.04.001_bib0033","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.clml.2026.04.001_bib0034","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia (ADAGIO study)","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2026.04.001_bib0035","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3324\/haematol.2014.104075","article-title":"Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia","volume":"99","author":"Rea","year":"2014","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.clml.2026.04.001_bib0036","first-page":"214","article-title":"Health care resource utilization and costs in patients with chronic myeloid leukemia with better adherence to tyrosine kinase inhibitors and increased molecular monitoring frequency","volume":"23","author":"Latremouille-Viau","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"10.1016\/j.clml.2026.04.001_bib0037","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/cncr.33267","article-title":"The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States","volume":"127","author":"Seymour","year":"2021","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.clml.2026.04.001_bib0038","first-page":"655","article-title":"Effectiveness and cost-utility of three first-line treatments in chronic myeloid leukemia - an Austrian healthcare perspective","volume":"16","author":"Rochau","year":"2013","journal-title":"Value Health"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:56:36Z","timestamp":1785239796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2152265026001011"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.04.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Timing of Tyrosine Kinase Inhibitor Switching in Chronic Myeloid Leukemia: A Comparative Analysis of Early Versus Late Strategies","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}